Ключевые слова
Аннотация
Ushbu tadqiqot surunkali yurak yetishmovchiligida davolash taktikasini individuallashtirish va uning uzoq muddatli klinik natijalarga ta’sirini baholashga bag‘ishlangan.
Tadqiqotda bemorlarning klinik holati, yurak funksiyasi, jismoniy faolligi, asosiy simptomlari va davolashga javobi o‘rganildi. Individual davo yondashuvida bemorning yurak funksional holati, arterial bosimi, buyrak faoliyati, hamroh kasalliklari va dori vositalariga tolerantligi hisobga olindi. Natijalar individual tanlangan va muntazam optimallashtiriladigan davolash strategiyasi simptomlarni nazorat qilish, funksional imkoniyatlarni yaxshilash va klinik barqarorlikni ta’minlashda muhim ahamiyatga ega ekanligini ko‘rsatdi.
Библиографические ссылки
Shahid I., Khan M.S., Fonarow G.C., Butler J., Greene S.J. Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure // Progress in Cardiovascular Diseases. - 2024. - Vol. 82. - P. 61–69.
Schuuring M.J., Treskes R.W., Castiello T. et al. Digital solutions to optimize guideline-directed medical therapy prescription rates in patients with heart failure: a clinical consensus statement // European Heart Journal – Digital Health. - 2024. - Vol. 5, No. 6. - P. 670–682.
Greene S.J., Butler J., Fonarow G.C. Rapid and intensive guideline-directed medical therapy for heart failure: 5 core principles // Circulation. - 2024. - Vol. 150, No. 6. - P. 422–424.
Ismail Z., Aboughdir M., Duric B. et al. Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024? // Expert Opinion on Pharmacotherapy. - 2024. - Vol. 25, No. 14. - P. 1887–1902.
Fibbi G., Sato R., Vatic M. et al. Pharmacological management of heart failure: a patient-centred approach // Expert Opinion on Pharmacotherapy. - 2024. - Vol. 25, No. 16. - P. 2151–2165.